SVB Leerink Downgrades AVEO Pharmaceuticals to Market Perform

SVB Leerink analyst Andrew Berens downgrades AVEO Pharmaceuticals (NASDAQ:AVEO) from Outperform to Market Perform.

byBenzinga Newsdesk

October 24, 2022

1 minute read

SVB Leerink analyst Andrew Berens downgrades AVEO Pharmaceuticals (NASDAQ:AVEO) from Outperform to Market Perform.

General
News

Stellantis Inks Deal For Fiat Vehicle Production In Algeria

By Shivani Kumaresan

October 13, 1:20 PM

Stellantis NV (NYSE:STLA) has signed a framework agreement with the Algerian Ministry of Industry. The agreement covers a project to develop…

STLA

Reported Late Thursday Feb 9, BriaCell Therapeutics Corp. Announces Results Of Shareholder Meeting; Approval Of The Company’s New Omnibus Equity Incentive Plan

By Happy Mohamed

February 10, 1:28 AM

BriaCell Therapeutics Corp. (NASDAQ:BCTX, BCTXW)))) (TSX:BCT) ("BriaCell" or the "Company"), a clinical-stage biotechnology company specializing in targeted immunotherapies for cancer, is pleased to

BCTX

Will Dogecoin Be The Biggest Meme Coin Gainer In January? How About For All Of 2022? Here’s What New Polls Are Saying

By Bibhu Pattnaik

January 15, 2:53 PM

Dogecoin (CRYPTO: DOGE) is currently ranked the 11th biggest cryptocurrencies in the market due to its growing community of holders and supporters.

$DOGE

What’s Happening With Sonnet BioTherapeutics Stock?

By Vandana Singh

August 19, 10:41 AM

Trading of Sonnet BioTherapeutics Holdings Inc (NASDAQ: SONN) stock was halted thrice during the early morning session. No company-specific reports are driving up the stock price today, so it appears there are external factors at play.

SONN

SVB Leerink Downgrades AVEO Pharmaceuticals to Market Perform

Related Posts

Stellantis Inks Deal For Fiat Vehicle Production In Algeria

Reported Late Thursday Feb 9, BriaCell Therapeutics Corp. Announces Results Of Shareholder Meeting; Approval Of The Company’s New Omnibus Equity Incentive Plan

Will Dogecoin Be The Biggest Meme Coin Gainer In January? How About For All Of 2022? Here’s What New Polls Are Saying

What’s Happening With Sonnet BioTherapeutics Stock?